<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Strukturierte Produkte
>
05.03.2019 20:36:00

Why Acadia Pharmaceuticals Stock Perked Up in February

Acadia Pharmaceuticals (NASDAQ: ACAD), a mid-cap biopharma, continued its recent rebound last month as its stock gained a healthy 16.5%, according to data from S&P Global Market Intelligence. The drugmaker's shares perked up in late February after the release of its upbeat fourth-quarter and full-year earnings report. Image source: Getty Images.Acadia's stock collapsed last year as the result of a CNN report questioning the safety of its Parkinson's disease psychosis medication Nuplazid. Since the start of 2019, however, the stock has regained a big chunk of this lost ground, thanks to the Food and Drug Administration reaffirming Nuplazid's risk-to-reward profile last September. The big deal is that Nuplazid no longer appears to be at risk of being pulled from the market over safety issues. Continue reading
Weiter zum vollständigen Artikel bei "MotleyFool"

Analysen zu ACADIA Pharmaceuticals Inc.mehr Analysen

23.07.19 ACADIA Pharmaceuticals Buy Needham & Company, LLC
10.12.18 ACADIA Pharmaceuticals Hold Canaccord Adams
07.08.18 ACADIA Pharmaceuticals Hold Stifel, Nicolaus & Co., Inc.

Eintrag hinzufügen

Die neue Welt der Kryptoanlagen | BX Swiss TV

Aktien in diesem Artikel

Finanzen.net News

pagehit
FinanzenNet.Finando.Web.Core.Areas.Article.ViewModels.News.DetailsViewModel FinanzenNet.Finando.Web.Core.Extensions.VueComponent ;